First look: tracking rare Drug's effects on pregnant patients and babies
NCT ID NCT07205666
Summary
This study aims to understand the safety of the medication eplontersen when taken during pregnancy or while breastfeeding. Researchers will collect and review health reports from pregnant or breastfeeding individuals who are taking the drug for a rare disease called transthyretin amyloidosis. The goal is to learn about any pregnancy complications or effects on the baby's health to build knowledge for future patients and doctors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGFrankfurt, Germany
Conditions
Explore the condition pages connected to this study.